TransCode Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $29.8M
- Price
- $1.76
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.12%
- Volume
- 29.8K
About
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Quick stats
Shares outstanding16.9M
Computed float2.8M
Float / shares16.5%
Cash runway (months)3.3
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001829635
AI Summary
AI-generated1/11
standardbullishclinical trial
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
TransCode Therapeutics reported updated Phase 1a data for TTX-MC138 showing a 71.4% stable disease rate (10 of 14 efficacy-evaluable patients) in heavily pretreated advanced solid tumors.
Disease control was durable: 57.1% of patients maintained control at three months, 35.7% at six months, and three patients remain progression-free at twelve months.
Tolerability was clean with no dose-limiting toxicities across dose levels up to 4.8 mg/kg, and exploratory RNA-sequencing showed dose-dependent antitumor immune activation supporting the mechanism.
The company is evaluating dose-expansion strategies, and a Phase 2a trial in ctDNA-positive colorectal cancer is underway; small sample size and going-concern funding risk remain key caveats.
Red flags
- small sample size (n=14 efficacy-evaluable); biomarker findings are hypothesis-generating
- 10-K risk factors disclose going-concern doubt and need for additional funding